Mast Therapeutics (SVRA) Stock Rating Lowered by BidaskClub

Mast Therapeutics (NASDAQ:SVRA) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Friday.

Several other brokerages have also commented on SVRA. Ladenburg Thalmann Financial Services began coverage on shares of Mast Therapeutics in a research note on Wednesday, January 3rd. They set a “buy” rating and a $35.00 price target on the stock. ValuEngine lowered shares of Mast Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research lowered shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, November 23rd. Roth Capital lowered their target price on shares of Mast Therapeutics from $40.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, October 31st. Finally, Canaccord Genuity raised their target price on shares of Mast Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $23.58.

Shares of Mast Therapeutics (NASDAQ SVRA) traded down $0.76 on Friday, hitting $11.87. 125,318 shares of the stock traded hands, compared to its average volume of 202,103. Mast Therapeutics has a 52 week low of $4.60 and a 52 week high of $17.19. The firm has a market cap of $340.26, a price-to-earnings ratio of -3.53 and a beta of 0.18. The company has a current ratio of 9.15, a quick ratio of 9.15 and a debt-to-equity ratio of 0.20.

Mast Therapeutics (NASDAQ:SVRA) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.12. research analysts anticipate that Mast Therapeutics will post -1.64 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Mast Therapeutics (SVRA) Stock Rating Lowered by BidaskClub” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/27/mast-therapeutics-svra-stock-rating-lowered-by-bidaskclub.html.

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Analyst Recommendations for Mast Therapeutics (NASDAQ:SVRA)

Receive News & Ratings for Mast Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply